BrainsWay develops advanced noninvasive neurostimulation treatments for mental health disorders. Its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology aims to improve health and transform lives. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder (OCD), and smoking addiction. The company's flagship technology is based on deep transcranial magnetic stimulation, aimed at helping smokers quit (FDA cleared since August 2020). BrainsWay's technology is based on patents filed by the US National Institutes of Health (NIH) and by the company. The company holds an exclusive license from the NIH for the patent and its technology. BrainsWay is FDA cleared for treating adult patients with major depressive disorder who have failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. BrainsWay is also approved in Canada for the treatment of major depressive disorder. It is also FDA cleared as an intended adjunct treatment for adult patients with obsessive-compulsive disorder. Furthermore, BrainsWay holds CE Mark clearance outside of North America for numerous additional psychiatric and neurological conditions including post-traumatic stress disorder and Alzheimer's disease. BrainsWay collaborates with scientists and academic research institutions worldwide in clinical trials covering various neuropsychiatric and neuroscience applications.